학술논문
A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
Document Type
article
Author
Sarah E. Greene; Yuefang Huang; Wooseob Kim; Mariel J. Liebeskind; Vinay Chandrasekaran; Zhuoming Liu; Parakkal Deepak; Michael A. Paley; Daphne Lew; Monica Yang; Mehrdad Matloubian; Lianne S. Gensler; Mary C. Nakamura; Jane A. O'Hallaran; Rachel M. Presti; Sean P.J. Whelan; William J. Buchser; Alfred H.J. Kim; Gary J. Weil
Source
Journal of Clinical Virology Plus, Vol 3, Iss 1, Pp 100135- (2023)
Subject
Language
English
ISSN
2667-0380
Abstract
Objective: Lateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination. Methods: We compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA. Results: The LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA. Conclusions: This simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.